A detailed history of Ensign Peak Advisors, Inc transactions in In8 Bio, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 829,176 shares of INAB stock, worth $232,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares
829,176
Previous 1,118,266 25.85%
Holding current value
$232,169
Previous $950,000 76.53%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.27 - $0.88 $78,054 - $254,399
-289,090 Reduced 25.85%
829,176 $223,000
Q4 2023

Feb 14, 2024

BUY
$0.69 - $2.34 $447,284 - $1.52 Million
648,238 Added 137.91%
1,118,266 $1.54 Million
Q2 2023

Aug 14, 2023

BUY
$1.05 - $3.24 $420,000 - $1.3 Million
400,000 Added 571.2%
470,028 $723,000
Q4 2021

Feb 11, 2022

BUY
$4.39 - $8.55 $307,422 - $598,739
70,028 New
70,028 $307,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.86M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.